H.C. Wainwright launched coverage of Pharming Group NV (AEX:PHARM) with a “buy” rating and €1.50 price target. The stock was recently quoted at €0.45.Read More
Stifel launched coverage of Selecta Biosciences (NASDAQ:SELB) with a “buy” rating and $23 price target. The stock closed at $14 on Friday.
“Selecta’s SVP-Rapamycin technology has the potential to open the doors of immunological tolerance and allow patients to be treated with recombinant protein ‘creations’ designed to combat disease,” writes analyst Thomas Shrader.Read More